Yale–Brown Obsessive Compulsive Scale

Proem Joins athenahealth's Marketplace Program to Bring Behavioral Health Clinical Decision Support to Healthcare Providers

Retrieved on: 
Thursday, August 3, 2023
Letter, Mini, Marketplace, SDS, Preface, DSM-IV codes, Research, YBOCS, Patient, Algorithm, Yale–Brown Obsessive Compulsive Scale, Mental health, Health information management, Nursing

ATLANTA , Aug. 3, 2023 /PRNewswire/ -- Proem Behavioral Health, a provider of the evidence-based clinical workflow software engine that helps healthcare providers triage patients and produce better mental health outcomes, today announced an agreement with athenahealth, Inc. through the company's Marketplace program. As part of the athenahealth® Marketplace, this newly integrated application is now available to athenahealth's growing network of healthcare providers to capture data at every step of the behavioral healthcare process. Key features of the Proem solution include:

Key Points: 
  • ATLANTA , Aug. 3, 2023 /PRNewswire/ -- Proem Behavioral Health, a provider of the evidence-based clinical workflow software engine that helps healthcare providers triage patients and produce better mental health outcomes, today announced an agreement with athenahealth , Inc. through the company's Marketplace program.
  • As part of the athenahealth ® Marketplace , this newly integrated application is now available to athenahealth's growing network of healthcare providers to capture data at every step of the behavioral healthcare process.
  • Key features of the Proem solution include:
    Gold-standard measures — Proem is the exclusive digital licensee of many of the world's leading behavioral health scales and measurements used in research and clinical practice for more than 25 years.
  • As a Marketplace partner, Proem joins a community of innovative, like-minded healthcare professionals working to bring best-in-class solutions to the athenahealth provider base.

Embark Behavioral Health Expands Virtual Intensive Outpatient Program to Serve Young Adults, Adds National OCD Track

Retrieved on: 
Wednesday, August 2, 2023
Online, Yoga, Yale–Brown Obsessive Compulsive Scale, IOP, Communication, Tic disorder, OCD, Music therapy, ERP, Building Bridges (residential program), Mindfulness, Betty Ford Center, Student, Martin Luther King Jr. Outpatient Center, Mental health, Family, Psychiatry, Family therapy, Caregiver, Y-BOCS, Nursing, Health care, Child, Embark

CHANDLER, Ariz., Aug. 2, 2023 /PRNewswire-PRWeb/ -- Embark Behavioral Health has expanded its insurance-reimbursed virtual intensive outpatient program, Embark Virtual IOP, to serve young adults, with it now available to young people ages 12-28. In addition, the company has added an obsessive-compulsive disorder (OCD) track to the online mental health service and made the IOP available in Missouri.

Key Points: 
  • Leading Network of Outpatient Centers and Residential Programs Now Offers Online Mental Health Services in 9 States, Bringing Quality Care to a Wider Population
    CHANDLER, Ariz., Aug. 2, 2023 /PRNewswire-PRWeb/ -- Embark Behavioral Health has expanded its insurance-reimbursed virtual intensive outpatient program, Embark Virtual IOP , to serve young adults, with it now available to young people ages 12-28.
  • In addition, the company has added an obsessive-compulsive disorder (OCD) track to the online mental health service and made the IOP available in Missouri.
  • "We're looking forward to the impact of Embark's growing presence in the online mental health realm with our expansions in ages, programming, and geographies served," said Tiffany King, vice president of Embark Behavioral Health virtual services.
  • To enhance its virtual services for youths and young adults, Embark Virtual IOP is offering an OCD track in all states where the online mental health program is available.

Obsessive-Compulsive Disorder (OCD) Epidemiology Outlook 2023-2032: Prevalence, Diagnosis, and Forecast

Retrieved on: 
Friday, July 28, 2023
Pharmaceutical, Health, Mental Health, EU4, Prevalence, OCD, Tic disorder, Disorder, Epidemiology, Obsessions, Obsessive–compulsive disorder, HIV disease progression rates, Patient, Yale–Brown Obsessive Compulsive Scale, Diagnosis, DSM-5, Y-BOCS, Pharmaceutical industry, Dentistry, DSM-IV

The "Obsessive-Compulsive Disorder - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Obsessive-Compulsive Disorder - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • Obsessive-compulsive disorder (OCD) has gained significant attention in the DSM-5, where it now has its own chapter.
  • The report offers a 10-year forecast and comprehensive coverage of the 7MM countries, with a detailed epidemiology segmentation for OCD.
  • The report provides valuable insights into the epidemiology of obsessive-compulsive disorder, including prevalence, diagnosis, and forecasts in the 7MM countries.

BrainsWay Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS™

Retrieved on: 
Wednesday, September 14, 2022
Income, Health, Yale–Brown Obsessive Compulsive Scale, Addiction, TMS, Cigna, Policy, MD, FDA, Brainsway, Y-BOCS, Transcranial magnetic stimulation, Disease, Brain, Food, Psychiatry, TASE, Tic disorder, U.S. Securities and Exchange Commission, World Health Organization, Knowledge, Company, Legislation, World, News, Review, Private Securities Litigation Reform Act, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, OCD, Technology, Quality of life, Disorder, Obsessions, Lists of diseases, Blue Cross Blue Shield Association, Health insurance, Deep, Leadership, Doctor of Philosophy, Tricare, Insurance, NASDAQ, Compulsions, WHO, De novo, Ageing, Research, Market access, GLOBE, Awareness, Failure, Medical device, Pharmaceutical industry, Medicare

Cigna will be issuing an updated revision to its TMS medical coverage policy effective September 15, 2022extending coverage to patients aged 18 and older diagnosed with OCD.

Key Points: 
  • Cigna will be issuing an updated revision to its TMS medical coverage policy effective September 15, 2022extending coverage to patients aged 18 and older diagnosed with OCD.
  • OCD is a difficult to treat disease, and almost half of the patients with OCD are treatment-resistant.
  • This positive coverage decision supplements the growing body of compelling clinical evidence supporting the treatment of OCD with our Deep TMS H7 Coil.
  • The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives.

Ceruvia Lifesciences Receives FDA Investigational New Drug Approval for Psilocybin Obsessive-Compulsive Disorder Program Phase 2 Trial

Retrieved on: 
Monday, June 27, 2022
FDA, Patient, CEO, Yale–Brown Obsessive Compulsive Scale, Principal investigator, Harvard Medical School, Investigational New Drug, New York University Grossman School of Medicine, Yale school, Psilocybin, Yale School of Medicine, Food, Partnership, OCD, Speech disorder, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Tic disorder, Pharmaceutical industry, Medicine

GREENWICH, Conn., June 27, 2022 /PRNewswire/ -- Ceruvia Lifesciences, a leading neurotransformational medicine biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug application for a Phase 2 clinical trial to determine the efficacy and safety of synthetic psilocybin (SYNP-101) in treating obsessive-compulsive disorder (OCD).

Key Points: 
  • GREENWICH, Conn., June 27, 2022 /PRNewswire/ -- Ceruvia Lifesciences, a leading neurotransformational medicine biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug application for a Phase 2 clinical trial to determine the efficacy and safety of synthetic psilocybin (SYNP-101) in treating obsessive-compulsive disorder (OCD).
  • "With positive preliminary results from a Ceruvia funded pilot Phase 2 study taking place at Yale School of Medicine, we are excited to have received FDA approval to begin our Phase 2 clinical trial to examine the efficacy and safety of psilocybin in treating OCD," said Carey Turnbull, Founder and CEO of Ceruvia Lifesciences.
  • Ceruvia's Phase 2, multicenter, randomized, double blind, active placebo controlled clinical trial will examine the safety and efficacy of synthetic psilocybin (SYNP-101) in treating OCD symptoms.
  • The trial plans to enroll a total of 105 participants who will receive 25mg of SYNP-101 or the active placebo, niaicin.

Ceruvia Lifesciences Receives FDA Investigational New Drug Approval for Psilocybin Obsessive-Compulsive Disorder Program Phase 2 Trial

Retrieved on: 
Monday, June 27, 2022
FDA, Patient, CEO, Yale–Brown Obsessive Compulsive Scale, Principal investigator, Harvard Medical School, Investigational New Drug, New York University Grossman School of Medicine, Yale school, Psilocybin, Yale School of Medicine, Food, Partnership, OCD, Speech disorder, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Tic disorder, Pharmaceutical industry, Medicine

GREENWICH, Conn., June 27, 2022 /PRNewswire/ -- Ceruvia Lifesciences, a leading neurotransformational medicine biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug application for a Phase 2 clinical trial to determine the efficacy and safety of synthetic psilocybin (SYNP-101) in treating obsessive-compulsive disorder (OCD).

Key Points: 
  • GREENWICH, Conn., June 27, 2022 /PRNewswire/ -- Ceruvia Lifesciences, a leading neurotransformational medicine biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug application for a Phase 2 clinical trial to determine the efficacy and safety of synthetic psilocybin (SYNP-101) in treating obsessive-compulsive disorder (OCD).
  • "With positive preliminary results from a Ceruvia funded pilot Phase 2 study taking place at Yale School of Medicine, we are excited to have received FDA approval to begin our Phase 2 clinical trial to examine the efficacy and safety of psilocybin in treating OCD," said Carey Turnbull, Founder and CEO of Ceruvia Lifesciences.
  • Ceruvia's Phase 2, multicenter, randomized, double blind, active placebo controlled clinical trial will examine the safety and efficacy of synthetic psilocybin (SYNP-101) in treating OCD symptoms.
  • The trial plans to enroll a total of 105 participants who will receive 25mg of SYNP-101 or the active placebo, niaicin.

OCD Awareness Week: We Need New Solutions, More Conversations

Retrieved on: 
Wednesday, October 13, 2021
Goodman, Solution, Multi-monitor, Awareness, LinkedIn, List of minor secular observances, Health, Compulsions, OCD, Population, Gold, Patient, Obsessions, Yale–Brown Obsessive Compulsive Scale, McIngvale, Baylor College of Medicine, Obsessive–compulsive disorder, Suicide, YBOCS, Baylor University, Medical device

OCD Awareness Week 2021 takes place October 1016.

Key Points: 
  • OCD Awareness Week 2021 takes place October 1016.
  • If you don't treat OCD effectively, this condition persists and often gets worse.
  • In addition to using the most current assessment solutions, Dr. Storch encourages those providing services to individuals with OCD to engage in meaningful discussions during OCD Awareness Week.
  • Storch and Young on the importance of OCD awareness, read the nView blog post " OCD Awareness Week: We Need New Solutions, More Conversations ."